Selecta Biosciences Inc

NASDAQ:SELB 4:00:00 PM EDT

1.31

-0.02 (-1.50%)

7:31:12 PM EDT: $1.34 +0.03 (+2.29%)

Market Cap (Intraday)	200.48M
Current PE	4.80
Forward PE	10.92
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$11.68 Million
Adjusted EPS	-$0.07

See more estimates

10-Day MA	$1.32
50-Day MA	$1.53
200-Day MA	$1.47

See more pivots

Selecta Biosciences Inc Stock, NASDAQ:SELB

480 Arsenal Way, 65 Grove Street, Watertown, Massachusetts 02472

United States of America

Phone: +1.617.923.1400

Number of Employees: 58

http://www.selectabio.com

Description

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.